Moderna, Inc. MRNA
We take great care to ensure that the data presented and summarized in this overview for Moderna, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRNA
View all-
Baillie Gifford & CO42.5MShares$1.68 Billion2.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.2MShares$1.59 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY25.6MShares$1.01 Billion0.07% of portfolio
-
State Street Corp Boston, MA16.8MShares$667 Million0.05% of portfolio
-
Theleme Partners LLP London, X07.23MShares$286 Million28.47% of portfolio
-
Geode Capital Management, LLC Boston, MA7.07MShares$280 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA5.22MShares$207 Million0.06% of portfolio
-
Flagship Pioneering Inc. Cambridge, MA4.63MShares$183 Million52.54% of portfolio
-
Invesco Ltd. Atlanta, GA4.03MShares$159 Million0.05% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL3.89MShares$154 Million0.07% of portfolio
Latest Institutional Activity in MRNA
Top Purchases
Top Sells
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at MRNA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 09
2024
|
Shannon Thyme Klinger Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
529
-2.52%
|
$23,276
$44.68 P/Share
|
Dec 06
2024
|
Shannon Thyme Klinger Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,138
+5.15%
|
-
|
Dec 03
2024
|
Shannon Thyme Klinger Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
112
-0.56%
|
$4,816
$43.3 P/Share
|
Dec 03
2024
|
Stephen Hoge President |
SELL
Open market or private sale
|
Direct |
314
-0.02%
|
$13,502
$43.3 P/Share
|
Dec 02
2024
|
Shannon Thyme Klinger Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
232
+1.15%
|
-
|
Dec 02
2024
|
Stephen Hoge President |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+0.05%
|
-
|
Nov 29
2024
|
James M Mock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,420
-11.37%
|
$59,640
$42.79 P/Share
|
Nov 29
2024
|
Shannon Thyme Klinger Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,418
-6.71%
|
$59,556
$42.79 P/Share
|
Nov 29
2024
|
Stephen Hoge President |
SELL
Open market or private sale
|
Direct |
291
-0.02%
|
$12,222
$42.79 P/Share
|
Nov 27
2024
|
James M Mock Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,981
+7.79%
|
-
|
Nov 27
2024
|
Shannon Thyme Klinger Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,981
+6.45%
|
-
|
Nov 27
2024
|
Stephen Hoge President |
BUY
Exercise of conversion of derivative security
|
Direct |
610
+0.04%
|
-
|
Nov 11
2024
|
Stephen Hoge President |
SELL
Open market or private sale
|
Direct |
277
-0.02%
|
$12,742
$46.1 P/Share
|
Nov 08
2024
|
Stephen Hoge President |
BUY
Exercise of conversion of derivative security
|
Direct |
523
+0.04%
|
-
|
Oct 07
2024
|
James M Mock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
715
-7.0%
|
$42,900
$60.12 P/Share
|
Oct 04
2024
|
James M Mock Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,453
+12.45%
|
-
|
Sep 09
2024
|
Shannon Thyme Klinger Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
551
-2.95%
|
$40,223
$73.57 P/Share
|
Sep 06
2024
|
Shannon Thyme Klinger Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,139
+5.74%
|
-
|
Sep 03
2024
|
Shannon Thyme Klinger Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
114
-0.64%
|
$8,664
$76.99 P/Share
|
Sep 03
2024
|
Stephen Hoge President |
SELL
Open market or private sale
|
Direct |
318
-0.02%
|
$24,168
$76.99 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 79.4K shares |
---|---|
Other acquisition or disposition | 26.8K shares |
Exercise of conversion of derivative security | 53.8K shares |
Open market or private sale | 721K shares |
---|